Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease
-
Add time:08/13/2019 Source:sciencedirect.com
Glutamate receptors were studied in the brains of controls and Parkinson's disease (PD) patients, of which 10 of 14 developed motor complications (dyskinesias and/or wearing-off) following levodopa therapy. 125I-RTI binding to the dopamine transporter and dopamine concentrations show comparable nigrostriatal denervation between the subgroups of PD patients. 3H-Ro 25-6981 binding to the NR1/NR2B NMDA receptor was increased in the putamen of PD patients experiencing motor complications compared to those who did not (+53%) and compared to controls (+18%) whereas binding remained unchanged in the caudate nucleus. 3H-AMPA binding was increased in the lateral putamen (+23%) of PD patients with motor complications compared to those without whereas it was decreased in the caudate nucleus of the PD patients (−16%) compared to controls. Caudate and putamen 3H-CGP39653 binding to NR1/NR2A NMDA receptor and NR1 subunit mRNA levels measured by in situ hybridization were unchanged in subgroups of PD patients compared to controls. These findings suggest that glutamate receptor supersensitivity in the putamen plays a role in the development of motor complications (both wearing-Off and dyskinesias) following long-term levodopa therapy in PD.
We also recommend Trading Suppliers and Manufacturers of levodopa isopropyl ester (cas 110301-07-0). Pls Click Website Link as below: cas 110301-07-0 suppliers
Prev:Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: Common implication of striatal neuropeptides
Next:(6aR)-11-Amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment08/15/2019
- (6aR)-11-Amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease08/14/2019
- Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: Common implication of striatal neuropeptides08/12/2019
- Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys08/11/2019
- Chiral lithium binaphtholate for enantioselective amination of acyclic α-alkyl-β-keto esters: Application to the total synthesis of l08/10/2019
- Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach08/09/2019
- Formulation and in vitro/in vivo evaluation of levodopa transdermal delivery systems08/08/2019
-
Health and Chemical more >
-
Related Products
- ISOPROPYL γ-FLUOROBUTYRATE
- Isopropyl (2S)-2-hydroxypropanoate
- Isopropyl 2-(3-nitrobenzylidene)acetoacetate
- Isopropyl 2,4-dichlorophenoxyacetate
- Isopropyl 2-bromo-2-methylpropanoate
- Isopropyl 2-cyanoacetate
- Isopropyl 2-methylbutanoate
- Isopropyl 3-amino-4-methylbenzoate
- Isopropyl 3-aminocrotonate
- Isopropyl 4-hydroxypiperidine-1-carboxylate


